Stock Ratings / Health Care / GYRE / forecast

WVE (32) APMD (47) SGMT (34) DSGN (45) ⌘ Pro Terminal →

Gyre Therapeutics Inc. (GYRE) 12-Month Stock Forecast & Price Target Cone

Q: What is GYRE's 12-month stock price target?

Gyre Therapeutics Inc. (GYRE) carries a 12-month consensus base price target of $6.06 (-5.5% from $6.41), with a bull-case target of $9.6 and a bear-case floor of $4.73.

Q: Is GYRE stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates GYRE D (Sell — SELL) with an RQD Confidence score of 46/100.

$6.41 -9.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.29

Gyre Therapeutics Inc. (GYRE) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $714.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.29 (-1.92%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GYRE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY GYRE SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (35% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 95.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 14.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$7.04-13.6% Next Q

Q2 (-2Q)

Grade C-$6.08-3.8% Next Q

Q3 (-1Q)

Grade D$5.85+9.6% Next Q

Current

Grade D$6.41-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GYRE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GYRE currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.73) and Max Pain ($6.73) forces dealer call-delta covering toward $9.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GYRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GYRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your GYRE Position Size: $10,000

Shares at $6.41: 1560.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.73

$7,379

$-2,621 (-26.2%)

12M Consensus BaseTarget $6.06

$9,454

$-546 (-5.5%)

12M Bull Case BreakoutTarget $9.60

$14,977

+$4,977 (+49.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$9	69%	B
JP MorganUS Large-Cap Research	SELL	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GYRE)

✓Walkthrough of GYRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GYRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.54%▲ ASCENDING CHANNEL

2026-10-30O $6.27H $6.41L $4.52C $6.41VOL 394.1K

RES: $8.12SUP: $5.90SMA50: $6.73SMA200: $6.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GYRE Butterfly Map → + Track GYRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

46.8%/yr Implied 5Y Growth

vs. +10.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GYRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GYRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GYRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GYRE)

Health Care Rank #448 of 1016 ⚔️ WVE vs GYRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GYRE vs. WVE, APMD, SGMT, DSGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Gyre Therapeutics Inc. (GYRE) ranks #448 by composite RQD confidence (46/100, grade D) and #398 by equity capitalization ($714.8M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. APMD currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with GYRE at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GYRE ACTIVE Gyre Therapeutics Inc.	D	46/100	72.3x	95.4%	25.4%	-9.59%	$714.8M	Benchmark Subject
WVE Wave Life Sciences Inc.	E	32/100	—	—	-35.0%	-0.28%	$715.9M	/wve-vs-gyre →
APMD Apnimed Inc.	D	47/100	—	—	—	-9.45%	$721.9M	/apmd-vs-gyre →
SGMT Sagimet Biosciences Inc. (Series A)	E	34/100	—	—	-35.0%	-2.89%	$735.7M	/sgmt-vs-gyre →
DSGN Design Therapeutics Inc.	D	45/100	—	—	-32.1%	-0.18%	$692.2M	/dsgn-vs-gyre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001124105

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gyre Therapeutics Inc. (GYRE) reported GAAP revenue of $116.6M (+10.2% vs. FY2024 revenue of $105.8M , and +2.8% cumulative change since FY2023) , GAAP net income of $9.9M, operating cash flow of $1.0M, and free cash flow of -$180.0K (+97.0% YoY). On the balance sheet, GYRE closed FY2025 with $219.8M in total assets against $0 in total debt (Altman Z-Score: 14.33, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$116.6M	$9.9M	$1.0M	-$180.0K	$219.8M	—
FY2024 (FY)	2024-12-31	$105.8M	$17.9M	-$3.6M	-$6.0M	$125.4M	—
FY2023 (FY)	2023-12-31	$113.5M	-$85.5M	$25.9M	$25.9M	—	—

3. GYRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Gyre Therapeutics Inc. (NASDAQ: GYRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $6.41 (-9.59% 1D, market cap $714.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GYRE ranks #448 in composite RQD confidence.

How does GYRE compare to WVE and APMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GYRE carries a Roarable D (46/100 RQD), trailing P/E of 72.3x, gross margin of 95.4%, and ROIC of 25.4%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and APMD (Apnimed Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $721.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GYRE?

Per GYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124105), Gyre Therapeutics Inc. generated $116.6M in revenue (+10.2% YoY), $9.9M in net income, and -$180.0K in free cash flow against $219.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GYRE trading relative to its 50-day, 200-day, and 52-week technical levels?

GYRE last traded at $6.41 (-9.59% on volume of 185,323 shares), positioning the stock -4.75% below its 50-day simple moving average ($6.73) and -8.30% below its 200-day simple moving average ($6.99). Across its 52-week range of $4.51 to $9.14, GYRE sits at the 41.0% percentile with a 14-day RSI of 29.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($5.61 to $7.21).

GYRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GYRE's 12-month stock price target?

Gyre Therapeutics Inc. (GYRE) carries a 12-month consensus base price target of $6.06 (-5.5% from $6.41), with a bull-case target of $9.6 and a bear-case floor of $4.73.

Is GYRE stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates GYRE D (Sell — SELL) with an RQD Confidence score of 46/100.

Direct Sub-Reports: GYRE RQD Cockpit GYRE 12M Forecast GYRE Earnings & Move GYRE Dividends & DRIP GYRE Insiders & 13F GYRE Whale Options GYRE Profit Sankey GYRE News & Why